Shen QD, et al. - Given the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma, researchers assessed its efficacy, safety, and feasibility as a first-line treatment in patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60–69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater. Analyses were done by intention to treat. In this single-arm, open-label, phase 2 clinical trial, the R-GemOx regimen was found to be highly efficacious and safe when given as a front-line treatment in an elderly patient subpopulation. The R-GemOx might be a therapeutic option for management of diffuse large B-cell lymphoma in elderly patients.